| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc6c2e9e63b6561f2f46b1de31f6379 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 |
| filingDate |
2005-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f41673e03cc8afd0f737762285751d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60191d9da088ed9c853e05d0e1f4b66f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b739be5134a3815cc711ae1fc0e3576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c94414d8c5e6b752b68d91f81ca31c6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d93f97e7f80520cb2ae1f8ffcf52ca52 |
| publicationDate |
2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CU-23468-B7 |
| titleOfInvention |
DOSAGE FORM OF PRAMIPEXOL IN A SINGLE DAILY DOSE |
| abstract |
An oral pharmaceutical composition comprising a therapeutically effective amount containing pramipexole or a pharmaceutically acceptable salt thereof. Said composition has at least one invitro release profile in which for half an hour no more than about 20% of pramipexole is divided into two hours after placing the composition in a solution and the pramipexole invivo. If a single dose of administration in human adults where the absorption time is 20% in two hours and the time to reach an average of 40% absorption is greater than about 4 hours. The composition is useful for oral administration of no more than one daily for subjects who have conditions or disorders for the AGONISTA dopomin receptor. |
| priorityDate |
2002-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |